Explain this page
Arphra AIPlain-English read on Dianthus Therapeutics, Inc.’s valuation06-09today
- DNTH Shares Surge 89% Over the Past Six Months: What's Driving It?2d
- Why Is Dianthus Therapeutics Stock Trading Higher On Friday?7d
- Dianthus Therapeutics, Inc. (DNTH) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript9d
- LBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis44d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
$3.52
-95.73% vs spot
Recommendation
Sell
5 of 5 methods
Method spread
0bull5bear
±5% threshold
Analyst PT consensus: $115.00 (+39.41%)
Candlestick · 1Y
Open in chart workstation →DNTH
82.51+55.15%H 93.61L 45.64MA50 82.69MA200 —Avg vol 1.0M
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.73% | +6.52% | -3.71% | +3.11% | +94.37% | +100.17% | +389.26% | +699.32% | -51.50% | -64.49% | -64.49% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$82.88
Bid
$69.00
20 sh
Ask
$91.81
75 sh
Spread
$22.810
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 Dec 2025 | $284K | $97.91M | $2.59 |
| Q3 Sep 2025 | $396K | -$36.77M | $-0.97 |
| Q2 Jun 2025 | $193K | -$31.63M | $-0.88 |
| Q1 Mar 2025 | $1.16M | -$29.51M | $-0.82 |
| Q4 Dec 2024 | $1.33M | -$28.44M | $-0.81 |
| Q3 Sep 2024 | $2.17M | -$25.17M | $-0.74 |
Sector & industry today
LiveSectors
- Technology+2.51%
- Communication Services+1.85%
- Utilities+1.35%
- Consumer Cyclical+0.30%
- Consumer Defensive-0.30%
- Energy-0.45%
- Industrials-0.48%
- Basic Materials-0.66%
- Financial Services-0.67%
- Real Estate-0.99%
- Healthcare-1.51%
Top industries (issuer's industry highlighted)
- Biotechnology+0.28%
- Oil & Gas Energy+8.53%
- Business Equipment & Supplies+5.82%
- Semiconductors+5.24%
- Electronic Gaming & Multimedia+5.23%
- Advertising Agencies-5.20%
- Medical - Equipment & Services+5.08%
- Grocery Stores-4.35%
- Financial - Mortgages+4.08%
- Broadcasting+4.00%
- Computer Hardware-3.67%
- Internet Content & Information+3.58%
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- DNTH Shares Surge 89% Over the Past Six Months: What's Driving It?zacks.com·Jun 17, 2026
- Why Is Dianthus Therapeutics Stock Trading Higher On Friday?benzinga.com·Jun 12, 2026
- Dianthus Therapeutics, Inc. (DNTH) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcriptseekingalpha.com·Jun 09, 2026
- LBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositisglobenewswire.com·May 05, 2026
- Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Resultsglobenewswire.com·May 05, 2026
Recent analyst activity
DB- Jun 10, 2026GradeBuy → BuyGuggenheim Defending Dianthus Therapeutics (DNTH): 'We reiterate our positive view'Guggenheim
- Jun 10, 2026GradeBuy → BuyDianthus price target raised to $132 from $110 at JefferiesJefferies
- Jun 10, 2026PT$132.00Dianthus price target raised to $132 from $110 at JefferiesJefferies
- Jun 10, 2026GradeBuy → BuyTD Cowen Defending Dianthus Therapeutics (DNTH): 'We see weakness as a buying opportunity'Cowen & Co.
- Jun 10, 2026GradeStrong Buy → Strong BuyRaymond James on Dianthus Therapeutics (DNTH) Amid 15% Down Day: 'We See Overall Positive Readthrough to Claseprubart'Raymond James
- Jun 10, 2026GradeOutperform → OutperformWolfe Research on Dianthus Therapeutics (DNTH): 'Not a negative but also not a strong positive'Wolfe Research
Peers
No peer list available for DNTH.
Total assets
$530.92M
Total debt
$1.39M
Cash & equiv
$51.09M
Operating CF
-$129.06M
Free cash flow
-$129.27M
Buybacks
$0
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $2.04M | -$177.93M | -$162.34M | $-4.20 | -7973.33% |
| FY 2024 | $6.24M | -$101.86M | -$84.97M | $-2.55 | -1362.77% |
| FY 2023 | $2.83M | -$48.17M | -$43.56M | $-8.45 | -1541.22% |
| FY 2022 | $6.42M | -$29.71M | -$28.48M | $-7.60 | -443.76% |
| FY 2021 | $1.48M | -$13.09M | -$13.11M | $-3.82 | -888.14% |